KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Other Accumulated Expenses (2018 - 2025)

Historic Other Accumulated Expenses for Emergent BioSolutions (EBS) over the last 8 years, with Q3 2025 value amounting to $24.1 million.

  • Emergent BioSolutions' Other Accumulated Expenses fell 6434.91% to $24.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.1 million, marking a year-over-year decrease of 6434.91%. This contributed to the annual value of $27.7 million for FY2024, which is 1529.05% down from last year.
  • Emergent BioSolutions' Other Accumulated Expenses amounted to $24.1 million in Q3 2025, which was down 6434.91% from $13.6 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Other Accumulated Expenses high stood at $122.0 million for Q1 2021, and its period low was $11.1 million during Q1 2025.
  • For the 5-year period, Emergent BioSolutions' Other Accumulated Expenses averaged around $41.8 million, with its median value being $27.7 million (2024).
  • As far as peak fluctuations go, Emergent BioSolutions' Other Accumulated Expenses surged by 150526.32% in 2021, and later tumbled by 7983.61% in 2022.
  • Quarter analysis of 5 years shows Emergent BioSolutions' Other Accumulated Expenses stood at $73.1 million in 2021, then crashed by 37.21% to $45.9 million in 2022, then decreased by 28.76% to $32.7 million in 2023, then dropped by 15.29% to $27.7 million in 2024, then decreased by 13.0% to $24.1 million in 2025.
  • Its Other Accumulated Expenses was $24.1 million in Q3 2025, compared to $13.6 million in Q2 2025 and $11.1 million in Q1 2025.